HR 7871 · in committee · significant

MVP Act

What this bill does

This bill allows drug manufacturers to use different price points in Medicaid value-based purchasing arrangements tied to clinical outcomes.
It affects Medicaid and Medicare drug pricing, pharmaceutical manufacturers, and patients using high-cost treatments like gene therapies.
The bill requires a GAO study of impacts and directs CMS to issue guidance on state implementation within Medicaid programs.

Generated by claude-haiku-4-5

Community Threads

Started by Cosponsor

01
How might allowing variable drug pricing based on clinical outcomes affect patients who cannot afford higher price points in value-based arrangements?
02
What evidence suggests that outcome-based pricing will improve treatment effectiveness compared to current flat-rate Medicaid drug pricing models?
03
Which states would bear administrative costs to implement these value-based purchasing arrangements, and how does that burden vary by state size?

Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.

Sponsor · R-KY-2

Brett Guthrie

Citizen cosponsors

In Congress

5/ 435

House Reps cosponsoring

Introduced 2026-03-09

Joining the bill

Legislative timeline

2026-03-09 · house · IntroReferral
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2026-03-09 · house · IntroReferral
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2026-03-09 · IntroReferral
Introduced in House
2026-03-09 · IntroReferral
Introduced in House

Citizen comments

No comments yet — be the first.